Cart
×
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 4-month interim results […]
Former Ducks Captain Continues to Fight Off the Ice to Find a Cure for Duchenne
An interview with the Millers and Ryan Getzlaf discussing the Getzlaf Golf Shootout that originally aired on NBC4
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506
– Initiation of LYNX Phase 2 clinical trial in individuals with DMD expected in Q4 2022 – Boulder, Colo., (September 7, 2022) – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage […]
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251
As an early funder of Dyne Therapeutics, CureDuchenne is pleased to share that Dyne has dosed the first participant in their clinical trial in Duchenne amenable to skipping exon 51.
Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on SRP-5051 […]
How to be a good friend to a Duchenne mom this Mother’s Day
Those gestures that you call “little things” are not little to us. The way you text or call just to check in makes me feel cared for. The cards you send when something heartbreaking has happened, makes me feel loved. The prayers you say for us when we aren’t even aware, the hugs, the long conversations we have – those are not little in my eyes. In fact, those are the very things that often keep me afloat somedays, and remind moms like me that we are not alone.
Dyne Therapeutics Announces “Breakthrough Article”
Published program data shows Dyne’s FORCE™ platform achieves enhanced exon skipping and prolonged dystrophin restoration in Duchenne in vivo mdx mouse model CureDuchenne provided funding to Dyne Therapeutics and we […]
Get in the Game
Accessible gaming for people with Duchenne Individuals with Duchenne are living at a time when technology is helping to make the digital world more accessible and the real world more […]